Sugi Predict

Sugi Predict / Compounds / SCHEMBL4816338

SCHEMBL4816338

SCHEMBL4816338

CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)Nc1cc2c3c(c(-c4ccccc4)[nH]c3c1)C=NNC2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 5/20 0.44
▸ ABL1 P00519 4/20 0.44
▸ AURKA O14965 3/20 0.44
▸ BCR P11274 3/20 0.44
▸ PLK4 O00444 2/20 0.44
▸ CHEK2 O96017 2/20 0.44
▸ EGFR P00533 2/20 0.44
▸ LCK P06239 2/20 0.44
▸ FYN P06241 2/20 0.44
▸ CDK1 P06493 2/20 0.44
▸ RET P07949 2/20 0.44
▸ FGFR1 P11362 2/20 0.44
▸ FGFR3 P22607 2/20 0.44
▸ RPS6KB1 P23443 2/20 0.44
▸ MARK3 P27448 2/20 0.44
▸ KDR P35968 2/20 0.44
▸ FLT3 P36888 2/20 0.44
▸ LIMK1 P53667 2/20 0.44
▸ BTK Q06187 2/20 0.44
▸ PRKAA1 Q13131 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13987224 0.87 AURKA (0.49) SRCABL1AURKABCRPLK4
SCHEMBL4778482 0.87 AURKA (0.49) SRCABL1AURKABCRPLK4
SCHEMBL4774217 0.87 AURKA (0.49) SRCABL1AURKABCRPLK4
SCHEMBL4775439 0.84 PTPN2 (0.48) SRCABL1AURKABCRPLK4
SCHEMBL4846956 0.80 AURKA (0.55) SRCABL1AURKABCRPLK4
SCHEMBL13987226 0.80 AURKA (0.46) SRCABL1AURKABCRPLK4
SCHEMBL4818890 0.78 AURKA (0.43) SRCABL1AURKABCRPLK4
SCHEMBL4773283 0.78 AURKA (0.45) SRCABL1AURKABCRPLK4
SCHEMBL13987152 0.78 AURKA (0.54) SRCABL1AURKABCRPLK4
SCHEMBL13987225 0.78 AURKA (0.48) SRCABL1AURKABCRPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462713-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS, INC. (US) 2008-12-09 — — US disclosed
US-7462713-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS, INC. (US) 2008-12-09 — — US disclosed
US-20070135415-A1 TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY AGOURON PHARMACEUTICALS, INC. 2007-06-14 — — US disclosed
US-20070135415-A1 TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY AGOURON PHARMACEUTICALS, INC. 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135415-A1 TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY CHEK1, CHEK2, CHKA SRC 467/4885ABL1 538/4885AURKA 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.